Professor CHAN Yap-Hang, Will

Prof Will Chan

Clinical Assistant Professor

  • MBBS, MRes(Med), MRCP(UK), FHKCP, FHKAM(Medicine), FRCP(Glasg)
email 2255 6382

Prof Chan is Clinical Assistant Professor of the University, and Honorary Associate Consultant Cardiologist at Queen Mary Hospital. He received overseas clinical training in Cambridge as Sir David Todd Memorial Scholar awarded by the Hong Kong College of Physicians, and holds Triple Fellowships in Cardiology, Advanced Internal Medicine, and Clinical Pharmacology. He received advanced Cardiology training in interventional Cardiac Electrophysiology at Royal Papworth Hospital, Cambridge, and was further trained as Senior Clinical Fellow in Cardiac Electrophysiology & Devices at Imperial College Healthcare NHS Trust, London.

Prof Chan has published more than 60 papers in international peer-reviewed journals, including First-authored articles in JAMA, JAMA Cardiology, JACC and European Heart Journal. He also served as reviewer for reputable journals including European Heart Journal, and JAMA Network Open. He is currently Associate Editor of JRSM Cardiovascular Diseases, and Honorary Secretary of Institute of Cardiovascular Science and Medicine, HKU.

Prof Chan is an awardee of the Hong Kong RGC Clinical Research Fellowship 2023/24, to innovate in cardiovascular drug repositioning research. He also currently serves as a Member of various drug panels of the Hong Kong Hospital Authority, including the Drug Management Committee and the Drug Advisory Committee.

Prof Chan’s clinical interests entail all areas of Clinical Cardiology including percutaneous interventions, cardiac arrhythmias, and implantable devices therapy. He established the Genetics Research Program For Personalized Medicine in Cardio-Oncology at HKU with support by the Li Shu Pui Medical Foundation Fellowship, with an aim of shedding lights on aetiology and fight against the clinical burden of heart diseases in cancer patients from the genetic perspective.

Research Profile
  1. Clinical Cardiology
  2. Clinical and Cardiovascular Pharmacology Innovations
  3. Atrial Fibrillation and Cardiac Arrhythmias
  4. Cardiac Oncology Research
  5. Mendelian Randomization and Therapeutic Target Prioritization
  6. Drug Repositioning Research and Randomized Controlled Trials

Selected Publications
  1. Chan YH .. Tse HF. Early Renal Dysfunction in Middle-Aged Adults Predicts Fatal and Nonfatal Cardiovascular Events. J Am Coll Cardiol. 2024 Jun 25;83(25):2711-2713. doi: 10.1016/j.jacc.2024.04.029.
  2. Chan YH, Hai JJ, Tse HF. Malignant Arrhythmia in a 40-Year-Old Man. JAMA Cardiology. 2018 Apr 18. doi: 10.1001/jamacardio.2017.4508.
  3. Chan YH (First and Corresponding Author), Schooling M. Performance of immunochemical fecal occult blood tests among users of low-dose aspirin. JAMA. 2011 Mar 16;305(11):1093 (Letter)
  4. Chan YH, .. Tse HF. Mendelian Randomization Focused Analysis of Vitamin D on the Secondary Prevention of Ischemic Stroke. Stroke. 2021 Sep 27:STROKEAHA120032634. doi: 10.1161/STROKEAHA.120.032634.
  5. Chan YH, Tse HF. Potassium homeostasis in patients with atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2019 Aug 21. pii: pvz034. doi: 10.1093/ehjcvp/pvz034.
  6. Chan YH, .. Yiu KH. Cumulative Rheumatic Inflammation Modulates the Bone-Vascular Axis and Risk of Coronary Calcification. J Am Heart Assoc. 2019 Jun 4;8(11):e011540. doi: 10.1161/JAHA.118.011540.
  7. Chan YH, .. Yiu KH. Osteogenic circulating endothelial progenitor cells are linked to electrocardiographic conduction abnormalities in rheumatic patients. Ann Noninvasive Electrocardiol. 2019 Sep;24(5):e12651. doi: 10.1111/anec.12651. Epub 2019 Apr 24. 
  8. Chan YH, ..Tse HF. Prolongation of PR interval is associated with endothelial dysfunction and activation of vascular repair in high-risk cardiovascular patients. J Interv Card Electrophysiol. 2013
  9. Chan YH, .. Tse HF. The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: role of incorporating PR prolongation. Atherosclerosis. 2014 Dec;237(2):504-13. doi: 10.1016/j.atherosclerosis.2014.08.026.
  10. Chan YH, .. Tse HF. Reduction of C-Reactive Protein with Isoflavone Supplement Reverses Endothelial Dysfunction in Patients with Ischaemic Stroke. Eur Heart J 2008 Nov;29(22):2800-7.doi: 10.1093/eurheartj/ehn409. Epub 2008 Sep 23.

Awards and Prizes
  1. Doris-Zimmern HKU-Cambridge Hughes Hall Fellowship 2024-25
  2. RGC Clinical Research Fellowship 2023/24, Hong Kong Research Grants Council
  3. Sir David Todd Memorial Scholarship 2022, Hong Kong College of Physicians
  4. Li Shu Pui Medical Foundation Fellowship 2022
  5. Li Shu Fan Medical Fellowship for Internal Medicine, The University of Hong Kong 2021/22
  6. Highest Ranking Abstract (Hong Kong), American College of Cardiology Annual Scientific Session, Washington D.C., USA 2017
  7. Young Investigator Award (Clinical), Honorable Mention, 9th Asia Pacific Heart Rhythm Society Scientific Session, Seoul, Korea 2016
  8. Outstanding Staff and Teams Award, Member of Cardiology Team (Cardiac Catheterisation Laboratory, Queen Mary Hospital), Hong Kong Hospital Authority 2019, in recognition of contribution to the outstanding achievement of the team
  9. Best Paper Awards, Hong Kong College of Cardiology Annual Scientific Congress (2013 and 2017)
  10. Best Poster Award, 6th Asia Pacific Heart Rhythm Society & Cardiorhythm 2013



Grant Record
  1. “PR Interval Prolongation-Induced Abnormal Vascular Function and Cardiovascular Death through Renin-Angiotensin-Aldosterone Activation: A Mendelian Randomization Study”, RGC ECS HKU 786012M (HK$1,045,744) (Principal Investigator)
  2. "Mendelian Randomization to Causally Infer the Impact of Life-Long Vitamin D Deficiency on Cardiovascular Disease and Death: Implications for Community-Based Cardiovascular Prevention", Health and Medical Research Fund 2012, Food and Health Bureau, Hong Kong SAR Government (HK$999,000) (Original Principal Investigator)
  3. “Research Program on Cardio-Oncology: Developing Holistic Heart Care for Cancer Patients”, Li Shu Pui Medical Foundation Fellowship/ Dean’s Fund, University of Hong Kong (HK$2,000,000) (Founding Co-Investigator)
  4. “Projecting ischaemic heart disease mortality and morbidity in Hong Kong”, Health and Health Services Research Fund 2010, Food and Health Bureau, Hong Kong SAR Government (Co-investigator) 
  5. “Assessing the Safety of Statin Use Among Adolescents Using Genetic Variations of 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR): A Mendelian Randomization Study”, Health and Medical Research Fund 2020, Hong Kong (Co-investigator)

Key Offices
  1. Member, Drug Advisory Committee, Hong Kong Hospital Authority 
  2. Member, Drug Management Committee, Hong Kong Hospital Authority
  3. Member, Drug Selection Committee, Hong Kong Hospital Authority
  4. Member, Committee on Special Programmes for Use of Drugs on Individual Patients, Hong Kong Hospital Authority
  5. Associate Editor, JRSM Cardiovascular Diseases
  6. Associate Editor in Cardiac Rhythmology, Frontiers in Cardiovascular Medicine
  7. Honorary Secretary, Institute of Cardiovascular Science and Medicine, The University of Hong Kong